OPKO Health’s ModeX Signs an Exclusive Worldwide License and Collaboration Agreement with Merck to Develop MDX-2201 for Epstein-Barr Virus Vaccine
Shots:
- OPKO will receive $50M up front and is eligible to receive ~$872.5M milestones associated with progress in the development and commercialization of MDX-2201 along with royalties on global sales
- Both companies will work together to advance the submission of an IND for MDX-2201 while Merck will be responsible for clinical and regulatory activities along with the product commercialization
- The agreement helps to advance MDX-2201 by using ModeX’s biologics platform to target multiple Epstein-Barr virus proteins. A joint steering committee made up of representatives from both companies will oversee the pre-IND filing activity
Ref: OPKO Health | Image: OPKO
Related News:- Merck Reports P-III Trial (STELLAR) Results of Sotatercept for Pulmonary Arterial Hypertension
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
